A retrospective analysis of plasma samples from a phase III trial (ASPECCT) in a large number of colorectal cancer patients revealed that the EGFR S492R mutation developed in 16% of patients in the cetuximab arm (Fig. 1b, bottom)20. This evidence concerns the gene EGFR and colorectal cancer.